Despite much discussion by politicians, commentators, and special interest groups, capital gain tax policy has remained largely unchanged since 1990. In 2021, the incoming Biden administration threatens to disrupt the status quo through a progressive tax policy that will have near-term and long-term ramifications throughout the private equity market.
The private equity market entered 2020 riding 10+ years of momentum. However, the COVID-19 pandemic and associated market uncertainty have put the brakes on new deals and forced investors to alter their strategies. While some reactionary GP strategies were focused on near-term survival, we predict others are here to stay as investors adopt to the “new normal”.
A private equity-backed biopharmaceutical drug developer develops indication roadmap for phase 3 clinical trials and commercialization.Read more: PE-Backed Drug Developer Case Study
A channel dynamics evaluation to support potential mezzanine and platform provider acquisition strategy.Read more: PE Firm Evaluates the Mezzanine Market Case Study
Private equity firm assesses string of legacy brand acquisitions in OTC market.Read more: OTC Brand Diligence for PE Sponsor Case Study